论文部分内容阅读
目的:观察化纤散联合保肝药物治疗肝脏纤维化患者的临床效果。方法:将112例肝脏纤维化患者随机分为观察组与对照组各56例,对照组给予常规保肝治疗,观察组在对照组治疗基础上加用化纤散治疗,对比2组的临床疗效及治疗前后肝功能指标[谷丙转氨酶(ALT)、谷草转氨酶(AST)]、肝脏纤维化生化指标[透明质酸(HA)、Ⅲ型前胶原酶(PCⅢ)、Ⅳ型胶原酶(Ⅳ-C)、层粘连蛋白(LN)]以及转化生长因子(TGF)-β1的变化。结果:观察组总有效率为92.9%,对照组总有效率为71.4%,2组比较,差异有统计学意义(P<0.01)。治疗后,2组ALT、AST、HA、PCⅢ、Ⅳ-C、LN及TGF-β1均较治疗前降低(P<0.01),观察组各指标值均低于对照组(P<0.01)。结论:化纤散联合保肝药物治疗能够有效缓解肝脏纤维化患者的临床症状体征,改善肝功能,逆转肝脏纤维化进程。
Objective: To observe the clinical effect of chemical fibrosis combined with hepatoprotective drugs in liver fibrosis patients. Methods: A total of 112 patients with liver fibrosis were randomly divided into observation group and control group, with 56 cases in each group. The control group was given conventional hepatoprotective therapy. The observation group was treated with chemical fibrosis on the basis of the control group. The curative effect was compared between the two groups. The indexes of liver function (ALT, AST), liver fibrosis biochemical indexes [HA, PCⅢ, Ⅳ-C ), Laminin (LN)], and transforming growth factor (TGF) -beta1. Results: The total effective rate was 92.9% in the observation group and 71.4% in the control group. There was significant difference between the two groups (P <0.01). After treatment, the levels of ALT, AST, HA, PCⅢ, Ⅳ-C, LN and TGF-β1 in both groups were significantly lower than those before treatment (P <0.01). The indexes in the observation group were lower than those in the control group (P <0.01). Conclusion: The treatment of liver fibrosis combined with liver fibrosis can effectively alleviate the symptoms and signs of liver fibrosis, improve liver function and reverse the process of hepatic fibrosis.